Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production
The etiology of multiple sclerosis has not yet been fully described. A potential link between the recombinant hepatitis B vaccine and an increased risk of onset or exacerbation of multiple sclerosis emerged in the mid-1990s, leading to several spontaneous reports and studies investigating this association. We conducted a critical systematic review aimed at assessing whether hepatitis B vaccination increases the risk of onset or relapse of multiple sclerosis and other central nervous system demyelinating diseases. MEDLINE and EMBASE were used as data sources, and the search covered the period between 1981 and 2011. Twelve references met the inclusion criteria. No significant increased risk of onset or relapse of the diseases considered was associated with hepatitis B vaccination, except in one study. Most studies included in this review displayed methodological limitations and heterogeneity among them, which rendered it impossible to draw robust conclusions about the safety of hepatitis B vaccination in healthy subjects and patients with multiple sclerosis. Therefore, on the basis of current data there is no need to modify the vaccination recommendations; however, there is a need to improve the quality of observational studies with emphasis on certain considerations that are discussed in this review.
KeywordsMultiple sclerosis Demyelinating disease Autoimmune disease Hepatitis B vaccine
We thank Prof. Florencio M. Ubeira (Departamento de Microbiología y Parasitología, Facultad de Farmacia, Santiago de Compostela, Spain) for critically reading the manuscript and his valuable comments.
Conflicts of interest
The authors declare no conflicts of interest.
- 1.Stratton K, Almario DA, McCormick MC (2002) Immunization Safety review: hepatitis B vaccine and demyelinating neurological disorders. National Academies Press, WashingtonGoogle Scholar
- 10.Waisbren BA Sr (2008) Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med Hypotheses 70:346–348Google Scholar
- 14.Touzé E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alpérovitch A (2000) The first episode of central nervous system demyelinization and hepatitis B virus vaccination. Rev Neurol (Paris) 156:242–246Google Scholar
- 18.DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT, for the Vaccine Safety Datalink Research Group (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60:504–509PubMedCrossRefGoogle Scholar
- 27.WHO Global Advisory Committee on Vaccine Safety (2004) Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled “Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis”. http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/. Accessed 25 May 2011
- 33.Lièvre M, Members of Epidemiology Working Group of French Pharmacovigilance Commission, Costagliola D, Evans S, Fourrier A, Imbs JL, Levy-Bruhl D, Merle L, Micallef J, Oger E (2009) Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 73:1426–1427PubMedCrossRefGoogle Scholar
- 38.Geier MR, Geier DA (2004) A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 22:749–755PubMedGoogle Scholar
- 42.WHO (2008) WHO Statistical Information System. http://apps.who.int/whosis/data/. Accessed 8 June 2011